[1] The battle towards HIV was never easy but people from Melbourne’s Burnet Institute or its China-based spinout Nanjing BioPoint are persistent in solving the dilemma.
[2] Nanjing BioPoint’s solution is aimed at ensuring that the diagnostic and continuing treatment pipeline is brought closer to home, enabling any local clinician to make sample collection.
[3] Burnett Institute’s Deputy Director David Anderson, Ph.D. says they’ve chosen to collaborate with China because of its growing economy and their government’s engagement to develop a biotechnology industry.
Want to keep up with the latest